ReviewPharmacogenomics2012
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.
Review in Pharmacogenomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs.Theranostics · 2020Review
- Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials.Journal of personalized medicine · 2019Review
- Predicting and Understanding the Human Microbiome's Impact on Pharmacology.Trends in pharmacological sciences · 2019Review
- Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity.Frontiers in pharmacology · 2017Review
- Mirror, mirror on the wall: which microbiomes will help heal them all?BMC medicine · 2016Article
- Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients.The pharmacogenomics journal · 2015Article
- The emerging era of pharmacogenomics: current successes, future potential, and challenges.Clinical genetics · 2014Review
- Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.Cold Spring Harbor perspectives in medicine · 2014Review
- Abacavir pharmacogenetics--from initial reports to standard of care.Pharmacotherapy · 2013Review
- Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.Journal of personalized medicine · 2013Article
- Relating human genetic variation to variation in drug responses.Trends in genetics : TIG · 2012Review
- Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.Expert review of molecular diagnostics · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
In the past decade, significant strides have been made in the area of cardiovascular pharmacogenomic research, with the discovery of associations between certain genotypes and drug-response phenotypes. While the motivations for personalized and predictive medicine are promising for patient care and support a model of health system efficiency, the implementation of pharmacogenomics for cardiovascular therapeutics on a population scale faces substantial challenges. The greatest obstacle to clinical implementation of cardiovascular pharmacogenetics may be the lack of both reproducibility and agreement about the validity and utility of the findings. In this review, we present the scientific evidence in the literature for diagnostic variants for the US FDA-labeled cardiovascular therapies, namely CYP2C19 and clopidogrel, CYP2C9/VKORC1 and warfarin, and CYP2D6/ADRB1 and β-blockers. We also discuss the effect of HMGCR/LDLR in decreasing the effectiveness of low-density lipoprotein cholesterol with statin therapy, the SLCO1B1 genotype and simvastatin myotoxicity, and ADRB1/ADD1 for antihypertensive response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.